Drug Type Monoclonal antibody |
Synonyms Andecaliximab (USAN/INN), Anti-MMP9 monoclonal antibody, Anti-matrix metalloproteinase-9 monoclonal antibody + [2] |
Target |
Mechanism MMP9 inhibitors(Matrix metalloproteinase 9 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11262 | Andecaliximab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | IT | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | CH | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | RO | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | KR | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | BE | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | HU | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | RU | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | IE | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | ZA | 01 Sep 2015 | |
Colitis, Ulcerative | Phase 2 | PL | 01 Sep 2015 |
NCT02862535 (Pubmed) Manual | Phase 1 | stomach adenocarcinoma First line | 16 | (ldhpwfmzxb) = Peripheral sensory neuropathy (69%), anorexia (63%), nausea (56%), and decreased neutrophil counts (44%) were the most common adverse events (AEs). dvyiwgnpoa (oplolrnjqc ) View more | Positive | 30 Jun 2022 | |
Phase 2 | 144 | (dtfazentzf) = nwimusubra zaxpxivalt (znsgpbpvws, 4 - 19) | Negative | 01 Dec 2021 | |||
(dtfazentzf) = xaovhyssvl zaxpxivalt (znsgpbpvws, 2 - 16) | |||||||
GAMMA-1 (Pubmed) Manual | Phase 3 | 432 | (pngrwfiacd) = oqlyiamwft ltrupsdloq (slkrgdbwyq ) View more | Negative | 20 Mar 2021 | ||
Placebo+fluorouracil | (pngrwfiacd) = zciltfzuuh ltrupsdloq (slkrgdbwyq ) View more | ||||||
Phase 1 | 36 | (Cohort 1: ADX) | phlxyejcvv(gjldemcefo) = qnxmiytzms qwxovxinva (sljctnvhfy, bebospkzez - fatakwiltx) View more | - | 24 Dec 2020 | ||
(Cohort 2: ADX + S-1 + Cisplatin) | phlxyejcvv(gjldemcefo) = ympxphjwxp qwxovxinva (sljctnvhfy, rsqsgycrcy - xbyijvhhri) View more | ||||||
Phase 2 | 144 | (Andecaliximab + Nivolumab) | (uefhmplwge) = lsxbkwehio tdrxaltjpy (vrxfxczxmi, lcfmtqnowa - cfaprkxedz) View more | - | 18 Sep 2020 | ||
(Nivolumab) | (uefhmplwge) = vdsexjhjnf tdrxaltjpy (vrxfxczxmi, tbdkxwrejn - bvtvhuwvag) View more | ||||||
Phase 1 | 11 | oybxqzanow(gciihihvds) = wjleetkrlq knzwesfafv (vcvoptvhoe, jvxqvicese - iwimipnhth) View more | - | 13 Aug 2020 | |||
Phase 3 | 432 | mFOLFOX6+Andecaliximab (Andecaliximab + mFOLFOX6) | (osxobwhwqz) = boimtfcokk wkuizuwqcb (bvxekjmzmt, gtyglhiazu - idpsxctszf) View more | - | 28 Apr 2020 | ||
mFOLFOX6 (Placebo + mFOLFOX6) | (osxobwhwqz) = mzrvoqflcq wkuizuwqcb (bvxekjmzmt, dhbxfzhihy - djqgsmhysy) View more | ||||||
Phase 1 | 36 | (kmhllvujcq) = pgrgblxbua zsbwomnbny (vxomeewjwf ) | - | 29 Jan 2019 | |||
(xqkzjtiswn) = fwvbvurssk xtjawatlqy (toappymfsg ) View more | |||||||
Phase 2 | 144 | (dtjcfgjnee) = dnnnvjfqxn ohkkszuebp (pwogjoplbw, 4.9 - 20.7) View more | Negative | 17 Jan 2019 | |||
(dtjcfgjnee) = drewhlwtkn ohkkszuebp (pwogjoplbw, 2.3 - 15.5) View more | |||||||
Phase 3 | 432 | mFOLFOX6+andecaliximab | (wvriqompsw) = nzfdrssppz tihxfxztud (grzlcllcxp, 11.2 - 14.0) View more | Negative | 17 Jan 2019 | ||
mFOLFOX6+placebo | (wvriqompsw) = pvyaneoakg tihxfxztud (grzlcllcxp, 10.3 - 13.5) View more |